These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36869704)

  • 1. Characterization of Intestinal Mesenchymal Stromal Cells From Patients With Inflammatory Bowel Disease for Autologous Cell Therapy.
    Anbazhagan M; Geem D; Venkateswaran S; Pelia R; Kolachala VL; Dodd A; Maddipatla SC; Cutler DJ; Matthews JD; Chinnadurai R; Kugathasan S
    Stem Cells Transl Med; 2023 Mar; 12(2):112-122. PubMed ID: 36869704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine Mixtures Mimicking the Local Milieu in Patients with Inflammatory Bowel Disease Impact Phenotype and Function of Mesenchymal Stromal Cells.
    Barnhoorn MC; van der Meulen-de Jong AE; Schrama ECLM; Plug LG; Verspaget HW; Fibbe WE; van Pel M; Hawinkels LJAC; Schepers K
    Stem Cells Transl Med; 2022 Sep; 11(9):932-945. PubMed ID: 35984079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory-compliant conditions during cell product manufacturing enhance in vitro immunomodulatory properties of infrapatellar fat pad-derived mesenchymal stem/stromal cells.
    Kouroupis D; Bowles AC; Greif DN; Leñero C; Best TM; Kaplan LD; Correa D
    Cytotherapy; 2020 Nov; 22(11):677-689. PubMed ID: 32723596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.
    Duijvestein M; Vos AC; Roelofs H; Wildenberg ME; Wendrich BB; Verspaget HW; Kooy-Winkelaar EM; Koning F; Zwaginga JJ; Fidder HH; Verhaar AP; Fibbe WE; van den Brink GR; Hommes DW
    Gut; 2010 Dec; 59(12):1662-9. PubMed ID: 20921206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of human adipose mesenchymal stem cells in Crohn's colon fibrosis is improved by IFN-γ and kynurenic acid priming through indoleamine 2,3-dioxygenase-1 signaling.
    Ye Y; Zhang X; Su D; Ren Y; Cheng F; Yao Y; Shi G; Ji Y; Chen S; Shi P; Dai L; Su X; Deng H
    Stem Cell Res Ther; 2022 Sep; 13(1):465. PubMed ID: 36076306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.
    Saadh MJ; Mikhailova MV; Rasoolzadegan S; Falaki M; Akhavanfar R; Gonzáles JLA; Rigi A; Kiasari BA
    Eur J Med Res; 2023 Jan; 28(1):47. PubMed ID: 36707899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases.
    Grégoire C; Lechanteur C; Briquet A; Baudoux É; Baron F; Louis E; Beguin Y
    Aliment Pharmacol Ther; 2017 Jan; 45(2):205-221. PubMed ID: 27878827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Crohn's disease mesenteric mesenchymal stem cells and their extracellular vesicles on T-cell immunosuppressive capacity.
    Dadgar N; Altemus J; Li Y; Lightner AL
    J Cell Mol Med; 2022 Oct; 26(19):4924-4939. PubMed ID: 36047483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases.
    Che Z; Ye Z; Zhang X; Lin B; Yang W; Liang Y; Zeng J
    Front Immunol; 2022; 13():952071. PubMed ID: 35990688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis.
    Forte D; Ciciarello M; Valerii MC; De Fazio L; Cavazza E; Giordano R; Parazzi V; Lazzari L; Laureti S; Rizzello F; Cavo M; Curti A; Lemoli RM; Spisni E; Catani L
    Stem Cell Res Ther; 2015 Sep; 6(1):170. PubMed ID: 26353774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response of mesenchymal stromal cells (MSCs) to type 1 ex vivo cytokine priming: implications for MSC therapy.
    Burnham AJ; Foppiani EM; Goss KL; Jang-Milligan F; Kamalakar A; Bradley H; Goudy SL; Trochez CM; Dominici M; Daley-Bauer L; Gibson G; Horwitz EM
    Cytotherapy; 2023 Dec; 25(12):1277-1284. PubMed ID: 37815775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review.
    Ko JZ; Johnson S; Dave M
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33440772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of Tissue-Resident Mesenchymal Stem Cells in Chronic Ulcerative Colitis and Crohn's Disease.
    Grim C; Noble R; Uribe G; Khanipov K; Johnson P; Koltun WA; Watts T; Fofanov Y; Yochum GS; Powell DW; Beswick EJ; Pinchuk IV
    J Crohns Colitis; 2021 Aug; 15(8):1362-1375. PubMed ID: 33506258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel therapeutic approach for inflammatory bowel disease by exosomes derived from human umbilical cord mesenchymal stem cells to repair intestinal barrier via TSG-6.
    Yang S; Liang X; Song J; Li C; Liu A; Luo Y; Ma H; Tan Y; Zhang X
    Stem Cell Res Ther; 2021 May; 12(1):315. PubMed ID: 34051868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.
    Cassano JM; Schnabel LV; Goodale MB; Fortier LA
    Stem Cell Res Ther; 2018 Apr; 9(1):82. PubMed ID: 29615127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN-γ and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase.
    Lim JY; Kim BS; Ryu DB; Kim TW; Park G; Min CK
    Stem Cell Res Ther; 2021 Jan; 12(1):37. PubMed ID: 33413597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis.
    Duijvestein M; Wildenberg ME; Welling MM; Hennink S; Molendijk I; van Zuylen VL; Bosse T; Vos AC; de Jonge-Muller ES; Roelofs H; van der Weerd L; Verspaget HW; Fibbe WE; te Velde AA; van den Brink GR; Hommes DW
    Stem Cells; 2011 Oct; 29(10):1549-58. PubMed ID: 21898680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease.
    Ciccocioppo R; Bernardo ME; Sgarella A; Maccario R; Avanzini MA; Ubezio C; Minelli A; Alvisi C; Vanoli A; Calliada F; Dionigi P; Perotti C; Locatelli F; Corazza GR
    Gut; 2011 Jun; 60(6):788-98. PubMed ID: 21257987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in mesenchymal stromal cell therapy in the management of Crohn's disease.
    Ibraheim H; Giacomini C; Kassam Z; Dazzi F; Powell N
    Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):141-153. PubMed ID: 29096549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal Stromal Cells: New Generation Treatment of Inflammatory Bowel Disease.
    Wei S; Li M; Wang Q; Zhao Y; Du F; Chen Y; Deng S; Shen J; Wu K; Yang J; Sun Y; Gu L; Li X; Li W; Chen M; Ling X; Yu L; Xiao Z; Dong L; Wu X
    J Inflamm Res; 2024; 17():3307-3334. PubMed ID: 38800593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.